Pharmafile Logo
Pharmafocus logo
Advanced Search

diabetes

Showing 15 posts of 391 posts found.

Health secretary calls for global action on lifestyle conditions

September 21, 2011
cardiovascular, diabetes, respiratory, smoking

Health secretary Andrew Lansley has urged governments across the world to be “bold and determined” in working together to tackle …

News
Boehringer Ingelheim

Boehringer’s Trajenta launched in the UK

September 20, 2011
Sales and Marketing Boehringer, Trajenta, diabetes

Boehringer Ingelheim has launched its new diabetes drug Trajenta in the UK, with a price tag to match its rival …

News

Fresh scrutiny for new diabetes drugs

September 15, 2011
Sales and Marketing Byetta, GLP-1, Januvia, Merck, Novo Nordisk, Victoza, diabetes

Merck’s Januvia and Lilly’s Byetta face renewed safety questions this week as the European Association for the Study of Diabetes …

News

Takeda moves potential first-in-class diabetes drug into phase III

September 12, 2011
Research and Development, Sales and Marketing TAK-875, Takeda, diabetes

Takeda has moved its potential first-in-class diabetes candidate TAK-875 into phase III clinical trials. The company hopes TAK-875 will offer …

News
Boehringer - Lilly's Trajenta (linagliptin)

Boehringer-Lilly’s Trajenta wins European approval

August 26, 2011
Sales and Marketing Tradjenta, Trajenta, diabetes

Boehringer Ingelheim and Eli Lilly’s new type II diabetes drug Trajenta has been approved Europe. The European Commission backed Trajenta …

News
Diabetes injection

Sharp increase in NHS diabetes prescribing costs

August 25, 2011
Sales and Marketing GP prescribing, NHS, diabetes, prescribing

NHS prescribing for diabetes has risen sharply, largely driven by the disease’s growing prevalence in the UK. Spending rose 41% …

News

Afrezza could breathe new life into inhaled insulin market

August 15, 2011
Research and Development, Sales and Marketing diabetes, inhaled insulin, insulin, research and development news

New trials for MannKind’s investigational inhaled insulin drug Afrezza have been given the go-ahead by the FDA, potentially breathing new …

News

European reprieve for Takeda’s Actos

July 22, 2011
Sales and Marketing Actos, diabetes

Takeda’s Actos is likely to remain on the market in Europe but regulators want the diabetes drug to carry stronger …

News

Future of AZ-BMS diabetes drug in doubt

July 20, 2011
Research and Development, Sales and Marketing AstraZeneca, BMS, dapagliflozin, diabetes, research and development news

A US advisory committee has rejected an investigational compound for type II diabetes sufferers, throwing its future into doubt. Dapagliflozin, …

News

Takeda forced to withdraw Actos in France

July 11, 2011
Sales and Marketing Actos, Competact, Takeda, diabetes

Takeda has officially taken its diabetes drug Actos off the market in France at the request of the country’s medicines …

News
Eli Lilly & Company

Lilly prepares late-stage pipeline boost

July 1, 2011
Research and Development, Sales and Marketing autoimmune diseases, diabetes, lilly, neuroscience, oncology

Eli Lilly has highlighted diabetes, oncology, autoimmune diseases and neuroscience as key therapy areas within its growth strategy. Within these …

News

Treatment flexibility will improve adherence in diabetes, study suggests

June 29, 2011
Research and Development, Sales and Marketing diabetes, insulin

A third of patients with diabetes admit to regularly missing or not taking insulin treatment three days a month, according …

News
Boehringer Ingelheim Eli Lilly Trajenta linagliptin

CHMP backs Boehringer-Lilly diabetes drug Trajenta

June 27, 2011
Sales and Marketing Tradjenta, Trajenta, diabetes

Boehringer Ingelheim and Eli Lilly’s new type II diabetes drug Trajenta has been recommended for European approval. It was given …

News
Boehringer Ingelheim and Lilly's diabetes drug Tradjenta

Boehringer-Lilly launch diabetes drug Tradjenta in US

June 16, 2011
Sales and Marketing Boehringer Ingelheim, Tradjenta, diabetes, lilly

Boehringer Ingelheim and Eli Lilly’s new type II diabetes treatment Tradjenta has been launched in the US. Tradjenta (linagliptin) is …

News
Eli Lilly and Company

Lilly accused of anti-competitive practices

May 17, 2011
Amylin, Boehringer, diabetes, exenatide, lilly, linagliptin

Amylin Pharmaceuticals is suing Eli Lilly and Company for alleged anticompetitive activity around Lilly’s January agreement with Boehringer Ingelheim to …

News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026